Daniel Wiederkehr

Estimated prevalence of undiagnosed atrial fibrillation in the United States

Mintu P. Turakhia, Jason Shafrin, Katalin Bognar et al. · PLoS ONE · 2018 · 181 citations · Full text

Public Health, Cardiology, Geriatric Medicine +16

Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United States

Mintu P. Turakhia, Jason Shafrin, Katalin Bognar et al. · The American Journal of Cardiology · 2015 · 89 citations

Pharmacy, Cardiology, Internal Medicine +15

Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials

Steve Deitelzweig, Alpesh Amin, Yonghua Jing et al. · Journal of Medical Economics · 2012 · 89 citations · Full text

Pharmacy, Cardiology, Pharmacoeconomics +17

Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis

Alexander T. Cohen, Allison Keshishian, Theodore Lee et al. · Thrombosis and Haemostasis · 2020 · 42 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Warfarin Use and Stroke Risk Among Patients With Nonvalvular Atrial Fibrillation in a Large Managed Care Population

Steven Deitelzweig, Erin Buysman, Brett Pinsky et al. · Clinical Therapeutics · 2013 · 39 citations

Medicine, Cardiology, Pharmacotherapy +15